Takeda Agrees With Mirum Pharma For Approval, Commercialization Of Maralixibat In Japan

Mirum Pharmaceuticals, Inc. (MIRM) and Takeda Pharmaceutical Company Limited (TAK) have entered into an exclusive licensing agreement for the development and commercialization of maralixibat in Japan for Alagille syndrome, progressive familial intrahepatic
cholestasis, and biliary atresia. Under the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan.

Mirum has submitted a new drug application to the FDA for maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome. The NDA is currently under priority review with a PDUFA date of September 29, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Inditex SA were gaining around 6 percent in the morning trading in Spain after the clothing firm that owns Zara reported Wednesday significant growth in its first-quarter profit on higher revenues as well as the absence of a prior year provision. Regarding the second quarter to date, the company said its store and online sales in constant currency between May 1 and June 4 increased 16.. The U.S. Consumer Product Safety Commission or CPSC, along with Golden, Colorado-based Boppy Co., urged consumers to stop using recalled Boppy Newborn Loungers, following reports of more infant deaths. They also asked online marketplaces to stop selling the recalled product. The company in September 2021 had recalled over 3.3 million infant lounging pillows after it was connected with deaths of 8 Apple has unveiled a bunch of new products for its customers including its first spatial computer Vision Pro Headset. The tech major has also introduced iOS 17, 15-inch MacBook Air, iPadOS 17, TvOS 17 For Apple TV, WatchOS 10 For Apple Watch, New Mac Studio, Mac Pro, and M2 Ultra, among others. The Apple Vision Pro features visionOS, the world's first spatial operating system.
Follow RTT